Premium Nahrungsergänzungsmittel | artgerecht

Erythroderma: Causes, Symptoms and Treatment

Erythroderma is a severe skin condition in which more than 90% of the body surface is affected by redness and inflammation. It is considered a dermatological emergency.

Regular tips about health Regular tips about health

Things worth knowing about "Erythroderma"

Erythroderma is a severe skin condition in which more than 90% of the body surface is affected by redness and inflammation. It is considered a dermatological emergency.

What is Erythroderma?

Erythroderma (also called exfoliative dermatitis) is a serious and potentially life-threatening skin condition characterized by widespread redness (erythema), inflammation, and scaling affecting more than 90% of the total body surface area. The condition represents a dermatological emergency and requires immediate medical attention.

Causes

Erythroderma is typically not a disease on its own but rather the severe manifestation or progression of an underlying skin or systemic condition. The most common causes include:

Psoriasis: The most frequent cause, referred to as erythrodermic psoriasis
Eczema: Particularly atopic dermatitis can progress to erythroderma
Drug reactions: Medications such as antibiotics, antiepileptics, or allopurinol may trigger erythroderma
Cutaneous T-cell lymphomas: Especially Sézary syndrome is closely associated with erythroderma
Other skin conditions: Including pemphigus foliaceus, pityriasis rubra pilaris, or lichen planus
Idiopathic: In up to 30% of cases, no underlying cause is identified

Symptoms

The symptoms of erythroderma affect almost the entire body and can develop rapidly:

Widespread, intense skin redness covering more than 90% of the body surface
Severe scaling and peeling of the skin
Intense itching (pruritus)
Edema (fluid accumulation), particularly in the lower legs
Heat loss due to impaired skin barrier function, potentially leading to hypothermia
Systemic symptoms such as fever, chills, and fatigue
Lymph node enlargement (lymphadenopathy)
In severe cases: rapid heartbeat, circulatory complications, and electrolyte imbalances

Diagnosis

The diagnosis of erythroderma is primarily clinical, based on the characteristic skin appearance. Further investigations are needed to identify the underlying cause:

Medical history: Pre-existing skin conditions, current medications, underlying diseases
Skin biopsy: Histological examination of a tissue sample to determine the underlying condition
Blood tests: Full blood count, inflammatory markers, electrolytes, liver function tests, protein levels
Immunophenotyping: When cutaneous lymphoma is suspected
Allergy testing: To rule out allergic causes

Treatment

The treatment of erythroderma is complex and depends primarily on the underlying cause. In severe cases, hospitalization is required.

General Measures

Inpatient monitoring and circulatory stabilization
Correction of fluid and electrolyte losses
Temperature management through adjusted room conditions and dressings
Skin care with emollients to support barrier restoration

Cause-Specific Therapy

Psoriasis-related erythroderma: Systemic therapies including methotrexate, ciclosporin, or biologics (e.g., TNF-alpha inhibitors, IL-17 or IL-23 inhibitors)
Eczema-related erythroderma: Systemic corticosteroids, ciclosporin, or dupilumab
Drug-induced erythroderma: Immediate discontinuation of the causative medication
Lymphoma-associated erythroderma: Oncological treatment, e.g., extracorporeal photopheresis

Complications and Prognosis

Erythroderma can cause life-threatening complications, including:

Sepsis due to bacterial superinfection of the damaged skin
High-output heart failure caused by increased blood flow through the inflamed skin
Severe malnutrition resulting from increased protein loss through the skin

The prognosis largely depends on the underlying condition and the general health of the patient. Early and consistent treatment significantly improves outcomes.

References

Bolognia JL, Schaffer JV, Cerroni L. Dermatology. 4th ed. Elsevier; 2018.
Sigurdsson V, Toonstra J, Hezemans-Boer M, van Vloten WA. Erythroderma. A clinical and follow-up study of 102 patients. J Am Acad Dermatol. 1996;35(4):523-531.
World Health Organization (WHO). Skin diseases overview. Available at: https://www.who.int

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.